Panelists discuss how payers can evaluate BTK inhibitors by considering specific MS phenotypes and FDA indications rather ...

Panelists discuss how BTK inhibitors represent a promising new oral therapy class that could address both inflammatory and ...

Columnist Desiree Lama explores how living with MS led her to confront the comparison trap, ultimately finding strength in ...

Although MS is classified as an immune-mediated disease, that doesn’t automatically imply that it’s an autoimmune disease.In fact, research on the topic is relatively mixed, with some experts ...